Interview with Esther Lim, Managing Partner, Finnegan
Finnegan is a leader and expert on the topic of intellectual property and it entered Asia in the late 1980s with an office in Tokyo yet China only very recently.…
Address: Mirae Asset Tower 28/F, Unit A-B No. 166 Lujiazui Ring Road, Pudong Shanghai, China 200120,China
Tel: 86 21 6194 2000
Web: http://www.finnegan.com/en-US/locations/region.aspx?region=5
Finnegan has more than 40 years of experience in successfully navigating U.S. IP law. Finnegan works with clients of all sizes, from virtually every industry and technology to identify, protect, advocate, and leverage their most valuable IP assets. Finnegan guides U.S. organizations as well as multinational entities that wish to conduct business in the U.S. Foreign innovators entering the U.S. market are often surprised at the intricacies of the intellectual property legal system. Patent law is becoming increasingly complex, with regulatory and legislative changes having a dramatic impact on companies’ intellectual property and business strategies. Finnegan views this complexity as an opportunity to think creatively. Finnegan’s full range of IP experience—from idea protection and management to litigation and appeals—gives the company the perspective to anticipate potential issues and devise creative solutions.
Asia boasts some of the world’s most sophisticated markets and fastest growing economies. Innovative corporations and organizations across Asia turn to Finnegan to identify, protect, advocate, and leverage their most valuable IP assets. To meet the needs of Finnegan’s Asian clients conducting business in their headquarter countries or in the United States, Finnegan has established offices in Shanghai, Taipei, and Tokyo. The firm also has strong ties to the IP legal communities in Korea and India, and our attorneys regularly travel to these countries to speak at conferences and meet with clients.
Finnegan’s licensed Foreign Representative Office in China is located in the Pudong area of Shanghai, and Finnegan’s attorneys are able to serve clients anywhere in the greater China region. As Chinese companies continue to expand their markets, Finnegan is on the ground to assist them with their U.S. IP strategies and needs.
Finnegan is proud to have been active and involved in the Chinese community for many years. We have over 30 professionals who speak Chinese, many with degrees from Chinese universities. Our local outreach efforts have included seminars, educational programs, and roundtable discussions for both business groups and universities. We are particularly active in U.S. IP licensing matters in China.
Intellectual Property Law
Finnegan is a leader and expert on the topic of intellectual property and it entered Asia in the late 1980s with an office in Tokyo yet China only very recently.…
Over the past few years, innovative Swiss giant Roche has combined its position as the world’s number 1 biotech company and its strength in in vitro diagnostics to brand itself…
Chinese biotech Clover Biopharmaceuticals may have flown under the radar thus far but it has stepped into the global limelight recently by partnering with GSK to develop a vaccine from…
2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been…
Regular PharmaBoardroom contributor David Crean looks at how the ongoing global coronavirus outbreak has impacted the global economy, how the biopharmaceutical industry is responding, and what the longer-term consequences of…
Bing Xu, GM of Vital River Laboratories, shares the company’s development in the last 20 years; the challenges of advantages of their JV with Charles River Laboratories; the importance of…
This new issue of China Healthcare and Life Sciences Review (compiled in December 2019) provides a retrospective of the tremendous gains the Chinese healthcare industry made in 2019 while simultaneously…
Eurasia Group’s Aditya Bhattacharji examines the unfolding coronavirus outbreak, the prospects for China’s political and economic stability, and how healthcare firms should think about the path forward. China appears to…
Researchers at the Institut Pasteur in Paris have become the first in Europe to fully sequence the genome of the 2019-nCoV coronavirus – putting the Institut at the forefront of…
The Chinese healthcare market has transformed dramatically in the past few years. There have been many reforms centred around the country’s vision of becoming a healthcare technology powerhouse in the…
Dr Yuguang Wang, CEO of Maxinovel Pharmaceuticals, recaps his three decades of industry experience across Big Pharma, biotech and CRO organizations in China and the US, his motivation to establish…
2019 was a bumper year for biotech companies listing on the Hong Kong Exchange (HKEx), with nine pre-revenue biotechs and eight revenue-generating biotech and biotech-related firms, mostly originating from mainland…
Jens Ewert, Life Science and Health Care Industry Leader at Deloitte China, shares his perspectives on the growth of China’s Life Sciences and Healthcare market, the strong presence of Deloitte…
See our Cookie Privacy Policy Here
